Want to see APM full AI Analyst Report?
APM Stock Chart & Stats
$1.07
-$0.08(-4.69%)
At close: 4:00 PM EST
$1.07
-$0.08(-4.69%)
Day’s Range― - ―
52-Week Range$0.65 - $4.47
Previous CloseN/A
Volume172.64K
Average Volume (3M)113.32K
Market Cap
$6.37M
Enterprise Value$5.51M
Total Cash (Recent Filing)$874.24K
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Sep 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding6,346,823
10 Day Avg. Volume164,850
30 Day Avg. Volume113,319
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.61
Enterprise Value/Ebitda-1.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.1
Revenue Forecast (FY)$106.80M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe balance sheet shows improving leverage and a meaningful equity cushion, which reduces near-term refinancing risk and gives a clinical-stage biotech runway to fund R&D and regulatory milestones without immediate commercial cash flows. This structural buffer supports execution over months.
Narrowing Loss TrendA material narrowing of the net loss in 2025 versus 2024 suggests management is stabilizing costs or shifting program spending more efficiently. A sustained reduction in losses lowers future funding needs and extends runway, improving chances to advance clinical programs to value-driving inflection points.
Strategic Merger & U.S. DomesticationApproval to merge with DiamiR and domesticate to Delaware is a structural change: it combines therapeutics with diagnostics, adds board/incentive frameworks, and aligns capital structure with U.S. norms. This can broaden commercialization pathways, partner appeal, and access to U.S. capital over the medium term.
Bears Say
Absent Commercial RevenueRevenue effectively at zero indicates the company lacks commercial products and cannot self-fund development. Over a multi-month horizon this increases dependency on external financing or transaction proceeds, raising dilution and execution risk for clinical programs if capital markets tighten.
Persistent Cash BurnSustained negative operating and free cash flow underscores ongoing cash burn to support R&D. Even with some recent improvement, continued outflows require recurrent financing, which can dilute shareholders, delay programs if funding gaps emerge, and constrain strategic optionality.
Chronic UnprofitabilityRecurring large operating losses and volatile margins indicate the business has not reached scalable economics. If losses persist, the equity cushion may erode over time, making it harder to attract high-quality partners or finance late-stage development without onerous terms.
Aptorum Group News
APM FAQ
What was Aptorum Group Ltd’s price range in the past 12 months?
Aptorum Group Ltd lowest stock price was $0.65 and its highest was $4.47 in the past 12 months.
What is Aptorum Group Ltd’s market cap?
Aptorum Group Ltd’s market cap is $6.37M.
When is Aptorum Group Ltd’s upcoming earnings report date?
Aptorum Group Ltd’s upcoming earnings report date is Sep 15, 2026 which is in 75 days.
How were Aptorum Group Ltd’s earnings last quarter?
Currently, no data Available
Is Aptorum Group Ltd overvalued?
According to Wall Street analysts Aptorum Group Ltd’s price is currently Overvalued.
Does Aptorum Group Ltd pay dividends?
Aptorum Group Ltd does not currently pay dividends.
What is Aptorum Group Ltd’s EPS estimate?
Aptorum Group Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptorum Group Ltd have?
Aptorum Group Ltd has 6,346,823 shares outstanding.
What happened to Aptorum Group Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aptorum Group Ltd?
Currently, no hedge funds are holding shares in APM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptorum Group Ltd
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---